Recent Updates
Recently added Catalysts
CORT Negative Sentiment

Corcept Therapeutics Incorporated Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 21, 2026 to Discuss Your Rights – CORT

Key Takeaway: Corcept Therapeutics Incorporated has been sued in a class action securities lawsuit by Levi & Korsinsky, LLP. The lawsuit seeks to recover losses from investors who were affected by alleged securities fraud between October 31, 2024, and December 30, 2025. The complaint alleges that the company made misleading statements regarding its interactions with the FDA, particularly concerning the adequacy of its program for relacorilant, which could impact the approval of its new drug application (NDA). Investors have until April 21, 2026, to seek lead plaintiff status.
Price reaction · baseline $42.49 (2026-04-02 close) · 2 other CORT headline(s) in the window, move may be shared
day 0 close · peak
-3.9%

Market Sentiment Analysis

CONCERNS & RISKS

  • Corcept Therapeutics is facing a class action lawsuit for alleged securities fraud.
  • The lawsuit claims that the company made false statements regarding its interactions with the FDA.
  • There are concerns about the adequacy of the clinical program assessing relacorilant's effectiveness.
  • The FDA indicated significant issues could arise if Corcept submitted the NDA.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+283%
120-day peak, hindsight
Typical move
4.8%
average across 6 past catalysts
Lead asset
mifepristone+ fluvastatin
Phase 1 · Healthy Subjects

Full Press Release Details

NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated" or the "Company") (NASDAQ: CORT) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Corcept Therapeutics Incorporated investors who were adversely affected by alleged securities fraud between October 31, 2024 and December 30, 2025. Follow the link below to get more information and be contacted by a member of our team:
CORT investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: According to the filed complaint, defendants made false statements and/or concealed that: In light of the circumstances in which they were made, not false and misleading. In truth, the FDA had told Corcept that it had concerns about the adequacy of the program assessing relacorilant’s effectiveness in treating hypertension in patients with hypercortisolism, including the design of the GRACE study. The FDA had further told Corcept to expect significant issues with the review if Corcept was to submit the NDA. As a result, Defendants’ positive statements concerning their interactions with the FDA and their expectations that the relacorilant NDA would be approved, were materially false or misleading.
WHAT'S NEXT? If you suffered a loss in Corcept Therapeutics Incorporated during the relevant time frame, you have until April 21, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor

Frequently Asked Questions

What is the class action lawsuit about Corcept Therapeutics?

The lawsuit aims to recover losses for investors affected by alleged securities fraud.

What timeframe does the Corcept lawsuit cover?

The lawsuit covers the period from October 31, 2024, to December 30, 2025.

Is there any cost to participate in the class action?

Class members may receive compensation without any out-of-pocket costs or fees.

How can I contact Levi & Korsinsky for more information?

Contact Joseph E. Levi at jlevi@levikorsinsky.com or call (212) 363-7500.

What are the concerns raised in the lawsuit?

The lawsuit outlines misstatements about FDA interactions and relacorilant issues.

Last updated: Apr 6, 2026